Skip to content
Screener

Operating Income at other companies

Arvinas logo
ArvinasARVN
-$63.8M-189%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$75.61M+10.6%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$49.13M-216%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$13.3M+48.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$82.77M-31.2%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemThree Months Ended May 31, 2026Three Months Ended May 31, 2025Six Months Ended May 31, 2026Six Months Ended May 31, 2025
Research and development87,65378,096171,789147,759
General and administrative15,59414,28230,20525,936
Total operating expenses103,24792,378201,994173,695
Loss from operations(94,204)(48,322)(186,699)(111,186)
Interest and other income, net4,3985,6189,71912,131
Loss before income taxes(89,806)(42,704)(176,980)(99,055)
Provision for (benefit from) income taxes(271)760(271)760
Net loss$(89,535)$(43,464)$(176,709)$(99,815)

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s operating income?
Nurix Therapeutics, Inc. (NRIX) reported operating income of -$94.2M in Q1 2026.
How has Nurix Therapeutics, Inc.'s operating income changed year-over-year?
Nurix Therapeutics, Inc.'s operating income decreased by 95.0% year-over-year, from -$48.32M to -$94.2M.
What is the long-term trend for Nurix Therapeutics, Inc.'s operating income?
Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s operating income has grown at a 24.8% compound annual growth rate (CAGR), from -$117.89M to -$285.67M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Nurix Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude